Search results

 
You searched for:
Results: 39
1

Respiratory diseases

Chiesi Farmaceutici is fully committed to the care and improvement of the quality of life of people suffering from respiratory diseases including asthma and COPD (Chronic Obstructive Pulmonary Disease). Asthma and COPD are characterized by an airflow reduction in the respiratory flow and impaired...
2

Neonatology

Physiological delivery takes place between the 37th and the 42nd week of gestation. By that time, the foetus is fully formed and developed enough to be able to adapt to extra-uterine life. However, in some cases delivery may occur before the 37th week of gestation. In that case, the neonate is...
3

Rare diseases

The term “rare” applies to those diseases affecting a limited number of people with a prevalence below a given cut-off point, which is codified by the legislation of each individual country. The EU sets this threshold at 0.05% of the population, i.e. one case for every 2,000...
4

Special care

Chiesi is also focusing its attention on the treatment and care of patients suffering from chronic severe conditions treated primarily by specialists in the hospital setting, which can be potentially life threatening: Cystic Fibrosis and Solid Organ Transplantation.  Thanks to our...
5

History

The history of the Chiesi company is the history of a personal dream that became collective: “To create innovative tools with which to provide effective treatment”. For more information - Chiesi Group and Chiesi Central Eastern Europe (Chiesi Pharmaceuticals...
6

Home

-
7

Chiesi Bulgaria

Chiesi Bulgaria is a part of an international Group focusing on research, which develops and offers innovative pharmaceutical solutions of added value aimed at improving patients' quality of life.   We have always adhered to a series of corporate values in the pursuit of our company...
8

Management

-
9

Annual report

-
10

Chiesi in the World

-
11

Therapeutical Areas

-
12

Code of ethics, compliance and disclosure

Ethics & Compliance / Code of Ethics & Compliance   The Code of Ethics and Compliance expresses the Group’s commitment to operate not only in accordance with the laws and regulations currently in force but also with certain principles and rules of conduct of an ethical...
13

Patient organisations

List of Patient Organizations supported by Chiesi Bulgaria   in 2015:   Association “Organization of Thalassemia Patients in Bulgaria”   Partial support of the Organization of Thalassemia Patients in Bulgaria (OTPB) in conducting activities on the occasion of the...
14

Working at Chiesi

  Your career opportunity   It is the personnel that make a company what it is. Our employees are critical factors in the success of our company. Our team is characterized by personal commitment, experience and clear identification with the Group’s corporate values. Although we...
15

Contacts

The following contact details must to be used for comments or questions concerning our Company and cannot be used to report adverse event to our products or for medical questions. For this kind of reporting, please  refer to PHARMACOVIGILANCE
16

Legal information

Company name:      Chiesi Bulgaria Ltd. Managing Director:  MD Andrey Nikolaev Kenderov Principal office:      83 Gyueshevo Str., Business Centre Serdika, Ofiice 104, 1330 Sofia, Bulgaria Co. Reg. No:...
17

Disclaimer

Chiesi Bulgaria Ltd. has prepared the information contained on this website from various internal and external sources with due professional care. All information on this webpage is intended for health care professionals and contacts. For more information get in touch with our team.   Please...
18

Pharmacovigilance

Chiesi has a system of pharmacovigilance to assume liability for our medicinal products (whether marketed or under clinical development) and to take appropriate action when necessary. We ensure that all information relevant to the benefit-risk ratio of our medicines is continually evaluated. When...
19

Search result

-
20

News

-
21

DATA PRIVACY

Data privacy statement We are pleased about your visit to our website and your interest in our company and our products. We respect the privacy of all those who visit this website. Chiesi Bulgaria Ltd. is aware of the sensitivity of information and personal data in the area of pharmaceuticals and...
22

Chiesi Guidelines

Ethics & Compliance / Code of Ethics & Compliance   The Code of Ethics and Compliance expresses the Group’s commitment to operate not only in accordance with the laws and regulations currently in force but also with certain principles and rules of conduct of an ethical...
23

Disclosure

EFPIA As a member of EFPIA (European Federation of Pharmaceutical Industries and Associations) and ARPharM (The Association of the Research-based Pharmaceutical Manufacturer in Bulgaria) we are fostering the transparency on the interaction between the pharmaceutical industry and health care...
24

Credits

  This project was edited and produced by Dynamic Mind.
25

B Corp and Benefit Society

Chiesi is the largest global pharmaceutical group to be awarded B Corp Certification, a recognition of high social and environmental standards. It is an achievement to be proud of, and yet one that feels natural: caring for others lies at the root of health science and has always been at the heart...
26

Our approach

Sustainability has always been a primary concern in the way Chiesi operates and has increasingly become a focus with a view to shared value. Today, it represents a crucial element of the strategic vision of the company, which is committed to: adopting a governancesystem based on...
27

We ACT - Sustainability Manifesto

We live in a time of great change. The equilibrium of a planet exploited beyond its limits is continuously evolving. We ourselves have changed the way we live and view society. The most fragile and vulnerable pay the price: those who are often left behind in this rush to make progress.   At...
28

Sustainability Report

29

Supply Chain Sustainability

Code of Interdependence   As a certified B Corp company, the Chiesi Group introduced the new Chiesi "Code of Interdependence" in February 2020. This is a Suppliers Code of Conduct for strategic suppliers of the Group and forms the basis for future relationships with our...
30

Ethics and Transparency

Guaranteeing the highest ethical standards is a daily priority for Chiesi in every aspect of its business. This means doing business on the basis of the principles of legality, fairness, integrity, responsibility and transparency.    The Code of Ethics and Conduct expresses the...
31

Sustainability

-
32

Code of Interdependence

As a certified B Corp company, the Chiesi Group introduced the new Chiesi "Code of Interdependence" in February 2020. This is a Suppliers Code of Conduct for strategic suppliers of the Group and forms the basis for future relationships with our suppliers.   The Code of Interdependence is the...
33

Mission and values

Our Mission as a part of Chiesi Group is to be recognised - research-focused international Group, able to develop and commercialise innovative pharmaceutical solutions to improve the quality of human life. Our wish is to maintain a high quality entrepreneurial team characterised by...
34

Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic

  The Group commits €3 million for donations to support the ongoing emergency in Italy Sustained efforts designed to ensure continuity of supply-chain and production despite increased restrictions in Italy and around the world Company also announces a €1 million investment in...
35

Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support

  Company sponsors #wewearstripes social media campaign calling on participants to share photos to express support for people affected by rare diseases   Company to light up offices around the world including Italy, the United States, and Canada   BOSTON, Mass. - February 26,...
36

Chiesi Group: performance is up in 2020

Parma (Italy), March 9, 2021 – Growth continues at Chiesi, an international research-focussed pharmaceutical group based in Parma, Italy with 30 affiliates worldwide. The company’s turnover, which stood at €2 billion 229 million in 2020 with an increase of 11.8% compared to 2019,...
37

Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).

CAMBRIDGE, Mass. and Parma, Italy – September 16, 2020 – Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an...
38

Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences

New visual identity is the first public manifestation of Chiesi Group’s continued transformation as a B Corp certified business Patients’ experiences and perception of Chiesi at the heart of the new corporate identity   Parma (Italy), March 22, 2021 – Chiesi, the...
39

Chiesi accelerates path toward full sustainability despite Covid-19 pandemic

Ensuring continuing medical treatment for patients has been top priority during Covid-19 pandemic. Focus on Diversity & Inclusion in the workplace: 53% of all employees are women – ratio of female workers even higher in R&D (64%). All the company’s 2020 activities, data and...